Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Am J Transplant. 2020 Sep;20(9):2343-2355. doi: 10.1111/ajt.15879. Epub 2020 May 13.
Myeloid-derived suppressor cells (MDSCs) expand in an inflammatory microenvironment such as cancer and autoimmunity. To study if transplantation induces MDSCs and these cells regulate allograft survival, C57BL/6 donor hearts were transplanted into BALB/c recipients and endogenous MDSCs were characterized. The effects of adoptive transfer of transplant (tx), tumor (tm), and granulocyte-colony stimulating factor (g-csf)-expanded MDSCs or depletion of MDSC were assessed. MDSCs expanded after transplantation (1.7-4.6-fold) in the absence of immunosuppression, homed to allografts, and suppressed proliferation of CD4 T cells in vitro. Tx-MDSCs differed phenotypically from tm-MDSCs and g-csf-MDSCs. Among various surface markers, Rae-1 expression was notably low and TGF-β receptor II was high in tx-MDSCs when compared to tm-MDSCs and g-csf-MDSCs. Adoptive transfer of these three MDSCs led to differential graft survival: control (6 days), tx-MDSCs (7.5 days), tm-MDSCs (9.5 days), and g-csf-MDSCs (19.5 days). In combination with anti-CD154 mAb, MDSCs synergistically extended graft survival from 40 days (anti-CD154 alone) to 86 days with tm-MDSCs and 132 days with g-csf-MDSCs. Early MDSC depletion (day 0 or 20), however, abrogated graft survival, but late depletion (day 25) did not. In conclusion, MDSCs expanded following transplantation, migrated to cardiac allografts, prolonged graft survival, and were synergistic with anti-CD154 mAb.
髓源抑制细胞(MDSCs)在炎症微环境中扩增,如癌症和自身免疫。为了研究移植是否诱导 MDSCs 以及这些细胞是否调节同种异体移植物的存活,将 C57BL/6 供体心脏移植到 BALB/c 受体中,并对内源性 MDSCs 进行了特征描述。评估了过继转移移植(tx)、肿瘤(tm)、粒细胞集落刺激因子(g-csf)扩增 MDSCs 或 MDSC 耗竭的效果。在没有免疫抑制的情况下,移植后 MDSCs 扩增(1.7-4.6 倍),归巢到同种异体移植物,并在体外抑制 CD4 T 细胞的增殖。Tx-MDSCs 在表型上与 tm-MDSCs 和 g-csf-MDSCs 不同。在各种表面标志物中,与 tm-MDSCs 和 g-csf-MDSCs 相比,Rae-1 表达明显较低,TGF-β 受体 II 较高。这三种 MDSCs 的过继转移导致移植物存活的差异:对照(6 天)、tx-MDSCs(7.5 天)、tm-MDSCs(9.5 天)和 g-csf-MDSCs(19.5 天)。与抗 CD154 mAb 联合使用时,MDSCs 协同地将移植物存活时间从 40 天(单独使用抗 CD154)延长到 86 天,与 tm-MDSCs 联合使用时延长到 132 天,与 g-csf-MDSCs 联合使用时延长到 132 天。然而,早期(第 0 或 20 天)MDSC 耗竭会阻断移植物存活,但晚期(第 25 天)耗竭则不会。总之,移植后 MDSCs 扩增,迁移到心脏同种异体移植物,延长移植物存活,并与抗 CD154 mAb 协同作用。